Member Info for sharehunter3

come on the buyers
hoping they start to l9oad up to replace these sellers

where are the buyers
hoping for some to replace these sellers
would think they liking this lower price as these sellers clear

looks to be dropping more
more buyers needed when these sellers clear

my luck more selling now
hoping when they sell more buyers might be seen

hoping more buyers like todays news

after todays news seeing this down
and yet looking at buys
some good buys a £30k share buy
is it shorters that bringing this share price down
more news needed to try and keep share price up
shorters don't like to see news

there are buys coming in thinking might be big seller in background
or maybe its the shorters
like to put a high sell limit on shares to try and stop them being loaned out to shorters
have read this works on share boards in the past
don't actually know if does work ,

and again buy quote up slightly more
are the sellers now cleared for a while
also interesting to see how France now moving back up after starting to move back up here

buy price now moving back up some more already

patience might not be needed much longer at this share
now that directors have bought
bit more buying again
as some pick up the lower priced shares
a move up this afternoon will not be a surprise
if some of the 10% traders are starting to clear
my thinking might be getting closer to time when seeing this share price moving up to a higher level again

14th may rns
Sales, orders and commitments to purchase the test since the initial launch have significantly exceeded expectations and have been transformational for the Group; all indications are that the positive financial effects of this will continue. This is additional revenue to Novacyt's other operations at Primerdesign and Lab21 Products. The Directors believe the significant demand for the Company's COVID-19 test will continue through to the end of the year, and may extend well into 2021, as the global demand for COVID-19 testing continues to increase. Further revenues are also expected from the launch of the Company's COVID-19 related products described later, which include the Exsig™ Direct extraction reagent and mobile COVID-19 testing.

29 April rns
The visibility of the sales order book is transformational for the business

Graham Mullis, Chief Executive Officer of Novacyt, commented:
"The visibility of the sales order book is transformational for the business and it is becoming increasingly clear that this exceptional demand for our COVID-19 test could continue for some months. As a result, we continue to ensure we have significant capacity and flexibility in the manufacturing of our COVID-19 test.

Alansugareatyour
looking like plenty making use of this low price

think likely finish blue
might see the usual last 30 mins afternoon buying

Partycosta
good to see France on the up again
had not checked for awhile

another nice share buy of 3000 shares

5000 share buy

buy quote moved up slightly again

4000 share buy
nice buy for some one

B2HS2L
thanks for post
was also thinking news due soon on USA
Sales, orders and commitments to purchase the test since the initial launch have significantly exceeded expectations and have been transformational for the Group;

Sales, orders and commitments to purchase the test since the initial launch have significantly exceeded expectations and have been transformational for the Group; all indications are that the positive financial effects of this will continue. This is additional revenue to Novacyt's other operations at Primerdesign and Lab21 Products. The Directors believe the significant demand for the Company's COVID-19 test will continue through to the end of the year, and may extend well into 2021, as the global demand for COVID-19 testing continues to increase. Further revenues are also expected from the launch of the Company's COVID-19 related products described later, which include the Exsig™ Direct extraction reagent and mobile COVID-19 testing.